Australia's most trusted
source of pharma news
Monday, 17 November 2025
Posted 17 November 2025 AM
Two originator brands have new generics chasing them in the race to be the first competing brand on the PBS.
CSL Seqirus' intravenous iron therapy Ferinject faces another challenger, with Alphapharm registering its generic Ferrive on the ARTG. In the 12 months to September this year Ferinject earned $157.7 million in pre-rebate R/PBS reimbursements.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.